Novartis Ag

Five Prime Therapeutics, Inc.

Genentech, Inc.

Kathy Miller

Thomas Huber

Tinya Abrams

Steven Bruce Cohen

Kathrin Ulrike Tissot-Daguette

Siew Ho Schleyer

Catrin Finner

Majid Ghoddusi

Charles Kaplan

Christie P Fanton

Leonard G Presta

Jean-Michel Rene Rondeau

David Bellovin

Nels P Nielson

Maike Schmidt

Luis Borges

Jason Damiano

Clemens Dürr

Katherine Rendahl

Gloria Brattich

Derrick Houser

Felicia Kemp

Daniel Menezes

Hangil Park

Alessandro Palumbo

Nerissa Mendoza

Clemens DÜRR

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4. The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.

B7-H4 antibodies and methods and use thereof

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

B7-H4 antibodies and methods of use thereof

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Antibody drug conjugates

The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

cKIT antibody drug conjugates

The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.

Multivalent antibodies and uses therefor

Growing community of inventors

San Francisco, CA, United States of America

Kathy Miller